STATUS OF URINARY 15-F2t-ISOPROSTANE LEVELS IN GENERALIZED TONIC–CLONIC SEIZURE PATIENTS WITH LEVETIRACETAM IN A TERTIARY CARE HOSPITAL
Abstract
Objectives: The objective of the study was to analyze urinary 15-2t-isoprostane levels in epileptic patients with levetiracetam (LEV) and to compare the urinary 15-2t-isoprostane levels between the different age groups, smokers, and alcoholics.
Methodology: The study was conducted in a tertiary care hospital. Urinary 15-2t-isoprostane levels were assayed in epileptic patients taking LEV. Twenty patients were recruited. Urinary levels of 15-F2t-isoprostane determined by ELISA. The patient’s age, gender, height, weight, smoking, and alcoholic history were collected using pro forma. Statistical analysis of data was performed using SPSS version 23.0.
Results: A total of 20 participants recruited for the study. Among these, 70% were male and 30% were female. The mean weight and height were more in males compared to females. The mean 15-F2t-isoprostane level was significantly higher in males compared to females. More than 40% of the participants were in the age group of >40 years. However, the mean urinary 15-F2t-isoprostane level is higher in the age group of 19–30 years. Only 20% of the participants were smokers and alcoholics. Non-smokers and non-alcoholics had higher urinary 15-F2t-isoprostane levels compared to smokers and alcoholics.
Conclusion: The urinary 15-F2t-isoprostane levels were more in males, the age group of 19–30 years, non-smokers and non-alcoholics. However, the levels are lesser when compared to earlier meta-analysis study. This concludes that LEV may have antioxidant effect. There is a need for further studies with more sample size and correlation of LEV and urinary 15-F2t-isoprostane levels.
References
2. Stefan H, Halász P, Gil-Nagel A, Shorvon S, Bauer G, Ben- Menachem E, et al. Recent advances in the diagnosis and treatment of epilepsy. Eur J Neurol 2001;8:519-39.
3. Patel M. Mitochondrial dysfunction and oxidative stress: Cause and consequence of epileptic seizures. Free Radic Biol Med 2004;37:1951-62.
4. Scott RA, Lhatoo SD, Sander JW. The treatment of epilepsy in developing countries: Where do we go from here? Bull World Health Organ 2001;79:344-51.
5. Martinc B, Grabnar I, Vovk T. The role of reactive species in epileptogenesis and influence of antiepileptic drug therapy on oxidative stress. Curr Neuropharmacol 2012;10:328-43.
6. Ozden H, Kabay SC, Toker A, Ustüner MC, Ozbayer C, Ustüner D, et al. The effects of levetiracetam on urinary 15f-2t-isoprostane level in epileptic patients. Seizure 2010;19:514-6.
7. LaRoche SM, Helmers SL. The new antiepileptic drugs: Clinical applications. JAMA 2004;291:615-20.
8. Klitgaard H. Levetiracetam: The preclinical profile of a new class of antiepileptic drugs? Epilepsia 2001;42:13-8.
9. Varoglu AO, Yildirim A, Aygul R, Gundogdu OL, Sahin YN. Effects of valproate, carbamazepine, and levetiracetam on the antioxidant and oxidant systems in epileptic patients and their clinical importance. Clin Neuropharmacol 2010;33:155-7.
10. Van’t Erve TJ, Kadiiska MB, London SJ, Mason RP. Classifying oxidative stress by F 2-isoprostane levels across human diseases: A meta-analysis. Redox Biol 2017;12:582-99.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
